Aspira Women's Health Inc. · OTC:AWHL

Aspira Women's Health — Investor Presentation (November 2020)

42 slides from Aspira Women's Health's investor presentation, November 2020

  1. Slide 1: Multi-Modal Bioinformatics Solution for Ovarian Cancer

    Slide 1: Multi-Modal Bioinformatics Solution for Ovarian Cancer

    “: ASPIRA WOMEN’S EALTH Multi-Modal Biolnformatics Solution for Ovarian Cancer NASDAQ: AWH_ | November 2020

  2. Slide 2: Safe Harbor

    Slide 2: Safe Harbor

    SAFE HARBOR This presentation contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this presentation are forward-looking statements. These forward-looking statements include, am

  3. Slide 3: Presentation Overview

    Slide 3: Presentation Overview

    PRESENTATION OVERVIEW

  4. Slide 4: Our Mission

    Slide 4: Our Mission

    OUR MISSION Enable Early Ovarian Cancer Detection for All Ages and Ethnicities 4 Copyright © Aspira Women’s Health Inc., 2020. All Rights Reserved

  5. Slide 5: Investment Highlights

    Slide 5: Investment Highlights

    INVESTMENT HIGHLIGHTS 5 Copyright © Aspire Women's Health Inc., 2020. All Rights Reserved. COMMERCIAL STAGE COMPANY FDA-cleared multi-modal disease management approach to women's health, with core focus on ovarian cancer INTELLECTUA PROPERTY Strong intellectual property protecting methods and use FD

  6. Slide 6: Management Team

    Slide 6: Management Team

    MANAGEMENT TEAM Leadership team with significant industry and execution expertise KANON tens @labCorp @omenzym Valerie Palmieri President & CEO -¥20+ years of senior and excoutive leaderchip experience inthe ciagnostice and laboratory industry ‘Served in numerous sales, operations and executive lead

  7. Slide 7: Aspira Women's Health's Evolution

    Slide 7: Aspira Women's Health's Evolution

    ASPIRA WOMEN’S HEALTH’S EVOLUTION ONGOING : Replace Standard of Care & Save Lives OVA1 Plus foundation Ae in place to become — COMPLETED | NEW Sta ndard of Care OVA1 Plus Launch (Q4'18) : Payers (2018-2019) Payer Coverage: 5 out of 10 lives covered Guetinen COSTE inthe U.S. Bioinformatic Tools + Cur

  8. Slide 8: Introduction to Patient Lifecycle and Market

    Slide 8: Introduction to Patient Lifecycle and Market

    Introduction to Patient Lifecycle and Market “1 ASPI Pes WOMEN'S EALTH 8 Copyright © Aspira Women’s Health Inc., 2020. All Rights Reserved

  9. Slide 9: Large Market Opportunity with the Following Patient Profiles

    Slide 9: Large Market Opportunity with the Following Patient Profiles

    LARGE MARKET OPPORTUNITY WITH THE FOLLOWING PATIENT PROFILES HIGH RISK HEREDITARY OVARIAN CANCER MONITORING OVARIAN CANCER 7 Ke 2 PELVIC MASS (o) CA Large market Recurrence Monitoring Opportunity with 20M women in the U.S. 9 Copyright © Aspira Women’s Health Inc., 2020. All Rights Reserved. ee WOME

  10. Slide 10: Patient Lifecycle

    Slide 10: Patient Lifecycle

    PATIENT LIFECYCLE e Exdocueck Key Focus Area ENDOMETRIOSIS. Nex . ONLY Inherit JUST ACCEPTED - BENIGN On , DX + Aid in Detection PELVIC MASS HIGH RISK - Current Medical Research MANAGEMENT HEREDITARY Future Opportunity & Opinion Publication - No Surgery Planned OVARIAN CANCER Replace CA125 MONITORIN

  11. Slide 11: Large Benign and Malignant Pelvic Mass Market U.S. Only

    Slide 11: Large Benign and Malignant Pelvic Mass Market U.S. Only

    LARGE BENIGN AND MALIGNANT PELVIC MASS MARKET U-s. ONLY G Suboptimal diagnostics and high cost burden Large Opportunity Solutions Today Our Solutions Costs Pelvic Masses + (Endo + PCOS+ Fune. Cysts) G NONE - TAM: 17.0M Endo CHECK $22B (2023 Target Date) I Pelvic Masses (Benign, cancer, non-gyn) G CA

  12. Slide 12: Innovation Pipeline Timeline

    Slide 12: Innovation Pipeline Timeline

    INNO VaTION PIPELINE TIMELINE Q3 2019 weet 2018 a OF On :;GENETIX Qorus : BY ASPIRA LABS a Hereditary Cancer Carrier Screening 112 Copyright © Aspira Women's Health Inc., 2020. All Rights Reserved. Late 2021 / 1H2022 E 2000F 4 OT ASPIRA GENETIX Qe Teetnstoey rasneret A technology transfer for geneti

  13. Slide 13: Research collaboration announced November 19, 2020

    Slide 13: Research collaboration announced November 19, 2020

    Research collaboration announced November 19, 2020. 13

  14. Slide 14: Starting with Ovarian Cancer

    Slide 14: Starting with Ovarian Cancer

    Starting with Ovarian Cancer 114 Copyright © Aspira Women’s Health Inc., 2020. All Rights Reserve d.

  15. Slide 15: Presentation Stage and 5-Year Survival Rate

    Slide 15: Presentation Stage and 5-Year Survival Rate

    PRESENTATION STAGE AND 5-YEAR SURVIVAL RATE! Presentation Stage Incidence Five Year Survival Rate Stage |) L 15% 9 (Stage I!) Regional 21% 75% Clinical Need for a Diagnostic Solution with Adequate Predictive Value to: + Ensure earlier cancer detection + Accurately identify patients needing timely tr

  16. Slide 16: Root Cause: Inadequate Tools

    Slide 16: Root Cause: Inadequate Tools

    ROOT CAUSE: INADEQUATE TOOLS Category Tools Physical exam & ultrasound + CA-125 (offabel) + ROMA (ateratve) Pre-operative biopsy not recommended Copyright © Aspira Women’s Health Inc., 2020. All Rights Reserved. Limitations Subjective results due to specialists’ interpretation - Low sensitivity + Hi

  17. Slide 17: Current Care Pathway: Majority of Cases Uncertain

    Slide 17: Current Care Pathway: Majority of Cases Uncertain

    CURRENT CARE PATHWAY — MAJORITY OF CASES UNCERTAIN CLEARLY Watchful Waiting / Management of Symptoms Level A guideline | LEVELB for pelvic mass LEVELA - INEFFECTIVE CARE PATHWAY RESULTS GUIDELINE r Rest r 9, assessment results = epee ait @G Late-stage detection (65%)? . Pelvic Mass In ~/0% unclear e

  18. Slide 18: Standalone Risk Stratification

    Slide 18: Standalone Risk Stratification

    Standalone Risk Stratification CURRENT STATE: EARLY STAGE FALSE NEGATIVE RATE 31-59% A low false negative rate is critical for patient care Early Stage Early Stage False Sensitivity (%) Negativity Rate (%) Clinical assessment (CA)! 68.6 Ultrasound alone? CA125 alone’ ROMA (Ca125 & HE4) 36. Demonstra

  19. Slide 19: Improved Specificity: OVA1 Plus Reflex Offering

    Slide 19: Improved Specificity: OVA1 Plus Reflex Offering

    IMPROVED SPECIFICITY: OVA1 PLUS - OVA1/OVERA REFLEX OFFERING (Q4 2018) If Results Are... Reported Results are... Intermediate Risk OVA1® v (1) plus > OVA1® Markedly 4106 ovat! Overa? OVA plus % Diff ; (95%CI) (95% cl) (95%Cl) — OVA1 vs OVA1plus Premenopausal? Risk 507.0 H Low INTERMEDIATE ELEVATED S

  20. Slide 20: Improved Early Stage Detection: OVA1 Plus vs. Standard of Care

    Slide 20: Improved Early Stage Detection: OVA1 Plus vs. Standard of Care

    AIDS IN IMPROVED EARLY STAGE DETECTION: OVA1 PLUS VS. STANDARD OF CARE (STAGE | + II) Rate of Cancer MISSED 94% Improvement in reducing the rate of cancer missed ~ Rate of Cancer DETECTED ‘ 100% (31%) ) 50% hy & & ] - 0% cA-1251" Clinical Modified OVAIPlus OVAiPlus Assessment ‘ACOG™ and Clinical Ass

  21. Slide 21: Disparity Gap Review

    Slide 21: Disparity Gap Review

    Disparity Gap Review NON-WHITE WOMEN, AND AFRICAN-AMERICAN WOMEN IN PARTICULAR, DISPLAY SIGNIFICANTLY LOWER CA125 VALUES COMPARED TO CAUCASIAN WOMEN This disparity is found in healthy women, women at high risk for ovarian cancer, and women with ovarian cancer“) CA125 (%, Caucasian Value is 100%) BAB

  22. Slide 22: OVA1 Superiority Over CA125 in Black Women

    Slide 22: OVA1 Superiority Over CA125 in Black Women

    Disparity Gap Review OVA1° SUPERIORITY OVER CA125 IN BLACK WOMEN +CA125 has an unacceptable sensitivity for cancer detection in Black women OVA1 vs CA-125 OVA1 vs ROMA + Aug and Sept 2019 BLACK WHITE ary BLACK WHITE - 2 peer reviewed 100 publications published + OVA1® shows acceptable sensitivity fo

  23. Slide 23: Early Detection Lowers Total Healthcare Costs

    Slide 23: Early Detection Lowers Total Healthcare Costs

    EARLY DETECTION LOWERS TOTAL HEALTHCARE COSTS Cost Comparison of Early vs. Late Stage Detection’? Pre-Menopausal Late Stage Detection 93K medical claims U $224,922 tinal sanded study demonstrated that : el the use of OVA1 Plus $197,757 compared to CA-125 Il can lower total costs while improving care

  24. Slide 24: A Growing Total Addressable Market

    Slide 24: A Growing Total Addressable Market

    A Growing Total Addressable Market ot ASPIRA WOMEN'S HEALTH 24 Copyright © Aspira Women’s Health Inc., 2020. All Rights Reserved.

  25. Slide 25: Large and Growing Total Addressable Market

    Slide 25: Large and Growing Total Addressable Market

    LARGE AND GROWING TOTAL ADDRESSABLE MARKET Currently Addressable Opportunity PELVIC MASS DETECTION + Surgical triage or guided referral: ~300-400K U.S. patients! and low ri + ~5% AWH market share + Current/AWH: OVA1plus HEREDITARY GYNECOLOGIC CANCER RISK + Determining risk for gynecologic cancers wi

  26. Slide 26: Growing Salesforce - Driving Adoption

    Slide 26: Growing Salesforce - Driving Adoption

    GROWING SALESFORCE - DRIVING ADOPTION Full-Time Sales Representative Pedigree = AmbryGenetics bostonheart diagnostics? éCareDx Counsyl “ur Prine Transplant Cae Marketed direct! ENOMIND’ r 20 full-time to synecologist, performers 7 . ° ha rmony (“FTE”) gynecology incompanies |f ; territory supergroup

  27. Slide 27: Commercialization Strategy: Decentralized Testing

    Slide 27: Commercialization Strategy: Decentralized Testing

    COMMERCIALIZATION STRATEGY- US + EX US - DECENTRALIZED TESTING ) plus + Testing Performed in Hospital Systems/Large ALGORITHM (\a"’ Gyn Super Group WAREHOUSE + Increase distribution @ POC (Point of Care) 2AGTT CLOUD BASED sre + Test performed locally with access to Aspira BIOINFORMATICS CY. ntciss o

  28. Slide 28: International Commercial Strategy

    Slide 28: International Commercial Strategy

    INTERNATIONAL - COMMERCIAL STRATEGY 28 Copyright © Aspira Women's Health Inc., 2020. All Rights Reserved. Both OVA1/Overa have CE Mark PHILIPPINES Large prospective study in process HI-PRECISION diagnostics ISRAEL Q4 2018 - Coverage received in Israel by CLALIT + 2nd largest integrated delivery netw

  29. Slide 29: Aspira Women's Health Is at a Commercial Inflection Point

    Slide 29: Aspira Women's Health Is at a Commercial Inflection Point

    ASPIRA WOMEN’S HEALTH IS AT A COMMERCIAL INFLECTION POINT Total Physicians (Distinct Physicians) 3000 2500 2000 1500 1000 500 0 a Q2 Qs Q4 qi Q2 Q3 cr qa Q2 Q3 2018 2019 2020 2020 ©2020 29 Copyright © Aspira Wornen’s Health Inc., 2020. All Rights Reserved.

  30. Slide 30: Aspira Women's Health Is at a Commercial Inflection Point

    Slide 30: Aspira Women's Health Is at a Commercial Inflection Point

    ASPIRA WOMEN’S HEALTH IS AT A COMMERCIAL INFLECTION POINT Due to COVID-19 Closures PHASE 1 PHASE 2 3,900 HIRING HIRING 3,854 3,700 3,602 3,596 3500 COMMERCIAL . GROWTH PHASE 2.5x commercial S200 investment Y-o-¥ & 3,129 demonstrated positive 3,100 Launch of Decentralized Ob-Gyn reception Platform &

  31. Slide 31: A Review of Financials and Market Access

    Slide 31: A Review of Financials and Market Access

    A Review of Financials and Market Access

  32. Slide 32: Financial and Operating Performance

    Slide 32: Financial and Operating Performance

    FINANCIAL AND OPERATING PERFORMANCE it i Reimbi t Grow Base Margin Expansion eimbursemen' gales Markét Share Adoption Capture Revenue and and Leverage Profitability and Revenue Cycle Unit Growth Fixed. Costs Management FY19 VS. FY18 3Q2020 vs 2Q2020 CASH POSITION Product volume Product volume Cash S

  33. Slide 33: Reimbursement and Market Access

    Slide 33: Reimbursement and Market Access

    REIMBURSEMENT AND MARKET ACCESS Coverage: Patient Lives In Millions O0 G0 BU Montana Oklahoma <7] IGHMARK. GO ov Tennessee NewMexico Arizona HCSC eA Cigna added OVA1 to its Mlinois 120M national preferred coverage list in January 2019 51% of the population now under positive coverage 100M GOAL Targe

  34. Slide 34: Wrap Up and Conclusion

    Slide 34: Wrap Up and Conclusion

    Wrap Up and Conclusion 34 Copyright © Aspira Women’s Health Inc., 2020. Alll Rights Reserved.

  35. Slide 35: Catalyst Driven Momentum Through 2020

    Slide 35: Catalyst Driven Momentum Through 2020

    CATALYST DRIVEN MOMENTUM THROUGH 2020 {Pama usc EXPANDED MARKET ACCESS VIA CIGNA + Q1 2019: Cigna added OVA1 to its national preferred coverage list MEVICORE GUIDELINES IV PAYER COVERAGE (128M) =15 M lives added (167 M) {EXPANDED SALES TEAM HEREDITARY BREAST AND OVARIAN CANCER + Phase | hiring compl

  36. Slide 36: Enterprise Value: Compelling Growth Strategies

    Slide 36: Enterprise Value: Compelling Growth Strategies

    Enterprise Value COMPELLING GROWTH STRATEGIES Expand Product Pipeline; Expand TAM Offer pelvic disease diagnostic and prognostic solutions from puberty to cure from endometriosis and ovarian cancer Become the Standard of Care for Global Pelvic Mass Risk Assessment Leverage the Largest Specimen and D

  37. Slide 37: In Summary

    Slide 37: In Summary

    IN SUMMARY Where We Large Market Are Today Opportunity ; Commercial Stage Company a . Solving a Huge with FDA-cleared, Strong pipeline with a Global Healthcare Problem guideline, and payer 20M Market Opportunity ' endorsed technology ra Copyright © Aspira Women’s Health Inc., 2020. All Rights Reserv

  38. Slide 38: Appendix

    Slide 38: Appendix

    Appendix j H 38 Copyright © Aspira Women’s Health Inc., 2020. Alll Rights Reserved.

  39. Slide 39: Our Solution: OVA1 + Overa (OVA1 Plus)

    Slide 39: Our Solution: OVA1 + Overa (OVA1 Plus)

    OUR SOLUTION = OVA1° + OVERA® (OVA1 PLUS) Ova? + OVA1 evaluates the levels of five ovarian Function C e o nune Horm« cancer-associated markers in the blood Apolipoprotein Beta 2 Protein re mtteeat an CA-12511 Prealbumin Transferrin + Levels combined into single cancer risk score. Multi-variate Index

  40. Slide 40: OVA1 Plus Improves Early Stage Detection

    Slide 40: OVA1 Plus Improves Early Stage Detection

    OVA1 PLUS IMPROVES EARLY STAGE DETECTION Comparison of CA-125II vs. OVA1Plus CA-12511 ( Vee” Sensitivity Across All Ovarian Cancer Stages' Stage x (2) Stage Il x () Stage Ill Stage IV Sensitivity Across Menopausal Status’ Pre-menopausal x ~ Post-menopausal Sensitivity Across Histological Subtypes’ E

  41. Slide 41: Trusted Solution: Care Pathway Guidelines

    Slide 41: Trusted Solution: Care Pathway Guidelines

    TRUSTED SOLUTION: CARE PATHWAY GUIDELINES Published Evidence Ueland, et al Bristow, et al. Longoria, et al. Goodrich, et al. Forde, et al. Coleman, et al. Eskander, et al. Urban, et al. Brodsky, et al. Shulman, et al. Fredericks, et al. Dunton, et al. Zhang, et al. Dunton, et al. 1.1n 100% of allKey

  42. Slide 42: Protected Solutions: Strong IP

    Slide 42: Protected Solutions: Strong IP

    PROTECTED SOLUTIONS: STRONG IP Issued patents covering various Pending patent applications including ovarian cancer OVA1 and Overa biomarkers products GRANTED PENDING (Approx.) USA Ex US. Total USA Ex US. Total 42 Copyright © Aspira Women’s Health Inc., 2020. All Rights Reserved. 24

Source: Internet Archive copy of aspirawh.com

More decks from Aspira Women's Health Inc.

All 21 Aspira Women's Health decks